evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. the company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, pain, metabolic diseases, oncology, respiratory diseases, fibrosis, inflammation and infectious diseases. by leveraging this expertise, evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.\\evotec has long-term discovery alliances with partners including bayer, boehringer ingelheim, chdi, genentech, janssen pharmaceuticals, medimmune/astrazeneca, roche and ucb. in addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. these include partnerships with boehringer ingelheim and medimmune in the field of diabetes, with janssen pharmaceuticals in the field of depression and with roche in the field of alzheimer's disease.\\evotec is built on integrated drug discovery know-how of over 20 years and is a leading player in the drug discovery field. the company's headquarters are located in hamburg, germany. additional major operating sites exist in abingdon and manchester, uk; göttingen and munich, germany; princeton, watertown & branford, usa; verona,italy; basel, switzerland as well as toulouse, france. evotec has approx. 2000 employees worldwide.
pharmaceuticals
